# In Silico Analysis of Tat Exons to Increase the Efficacy of a Nef-Tat-based HIV-1 Vaccine Candidate

**Authors:** Leila Sadeghi, Fatemeh Heidarnejad, Azam Bolhassani, Elham Mohit, Parisa Moradi Pordanjani

PMC · DOI: 10.5812/ijpr-162036 · Iranian Journal of Pharmaceutical Research : IJPR · 2025-09-13

## TL;DR

This study uses computer modeling to compare two HIV vaccine designs, finding that one part of the Tat protein is more effective at triggering immune responses than the full version.

## Contribution

The study introduces an in silico approach to optimize an HIV-1 vaccine by comparing the immunogenicity of different Tat exon configurations.

## Key findings

- Both Nef-Tat constructs were antigenic, non-allergenic, and stable during simulations.
- Nef-Tat(exon 1) showed stronger activation of T- and B-cells compared to Nef-Tat(exons 1+2).
- Including Tat exon 2 did not improve the immunogenicity of the Nef-Tat fusion protein.

## Abstract

The global human immunodeficiency virus HIV/AIDS pandemic persists without complete eradication. Developing a safe and effective vaccine remains the most promising approach, but ongoing clinical trials have been unsuccessful due to the vaccines' inability to stimulate robust immunity.

The present research endeavor proposes an innovative therapeutic vaccine by employing immunoinformatics strategies. Herein, we aimed to compare the efficiency of the whole sequence of Tat(exons 1 + 2) with its first exon(exon 1) in a fusion vaccine construct harboring the whole sequence of the Nef protein [i.e., Nef-Tat(exons 1 + 2) and Nef-Tat(exon 1) fusion proteins] using in silico studies.

First, the secondary structures of both fusion proteins were predicted. Then, 3D models of the constructs were refined, and their physicochemical properties were determined. After analysis of toxicity, allergenicity, and antigenicity of constructs, the formation of ligand (constructs)-receptor (TLR-2 to TLR-5, and TLR-7 to TLR-9) complexes was examined using the ClusPro and HDOCK servers, and the highest scores of docking analysis were used for molecular dynamics (MDs) simulation. Finally, the JCat server was applied for codon optimization.

Our results indicated that both protein constructs were antigenic, non-allergenic, and capable of eliciting adaptive immune responses. The average values of radius of gyration (Rg) for Nef-Tat(exon 1) and Nef-Tat(exons 1+2) with TLR-4 were 1.74 and 1.90, respectively. Therefore, both constructs were stable. Moreover, the Nef-Tat(exon 1) construct could significantly activate both T- and B-cells as compared to the Nef-Tat(exons 1+2). Indeed, inclusion of the second exon of Tat(exon 2) did not enhance the immunogenicity of the Nef protein.

Generally, immunoinformatics studies showed the importance of Tat exon 1 in HIV-1 fusion vaccine design.

## Linked entities

- **Genes:** TAT (tyrosine aminotransferase) [NCBI Gene 6898], S100B (S100 calcium binding protein B) [NCBI Gene 6285]
- **Proteins:** TLR2 (toll like receptor 2), TLR4 (toll like receptor 4), TLR5 (toll like receptor 5), TLR7 (toll like receptor 7), TLR9 (toll like receptor 9)

## Full-text entities

- **Genes:** Nef [NCBI Gene 156110], TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, Tat [NCBI Gene 6898;155871], TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, TLR5 (toll like receptor 5) [NCBI Gene 7100] {aka MELIOS, SLE1, SLEB1, TIL3}
- **Diseases:** human immunodeficiency virus HIV/AIDS (MESH:D016263), toxicity (MESH:D064420)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12523967/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12523967/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12523967/full.md

---
Source: https://tomesphere.com/paper/PMC12523967